转移性前列腺癌是全世界的主要健康负担，需要不断开发有效的治疗策略。雄激素剥夺疗法仍然是前列腺癌治疗的基石，但转移性去势抵抗性前列腺癌（mCRPC）需要新的方法。最近的研究强调了 mCRPC 患者中 DNA 修复基因（包括 BRCA1 和 BRCA2）突变的普遍性，使他们更容易受到铂类化疗和聚（ADP-核糖）聚合酶（PARP）抑制剂的影响。基于铂类的化疗，特别是与紫杉烷类药物联合使用，在 mCRPC 中表现出令人鼓舞的活性，并且同源重组基因改变显示这些患者对铂类化合物的敏感性增加。铂类化疗与 PARP 抑制剂的组合代表了针对该亚组患者的一种新颖且可能有效的治疗策略。然而，施用这些药物的最佳顺序以及交叉耐药性和交叉毒性的可能性仍然需要进一步研究。前瞻性随机研究对于阐明针对这一具有挑战性的患者群体的最有效的治疗方法至关重要。本综述旨在探讨铂类化疗在前列腺癌中的潜力，并更详细地探讨同源重组修复（HRR）突变患者的潜力。我们讨论了铂类化合物与 PARP 抑制剂相结合的协同效应以及采用特定治疗序列的潜在益处。© 2023。作者。

Metastatic prostate cancer is a major health burden worldwide, necessitating the continuous development of effective treatment strategies. Androgen deprivation therapy remains the cornerstone of prostate cancer treatment, but novel approaches are needed for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have highlighted the prevalence of mutations in DNA repair genes, including BRCA1 and BRCA2, in mCRPC patients, rendering them more susceptible to platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors. Platinum-based chemotherapy, particularly in combination with taxanes, has demonstrated encouraging activity in mCRPC, as well as homologous recombination gene alterations have shown increased sensitivity to platinum compounds in these patients. The combination of platinum-based chemotherapy with PARP inhibitors represents a novel and potentially effective therapeutic strategy for this subgroup of patients. However, the optimal sequence of administering these agents and the potential for cross-resistance and cross-toxicities remain areas requiring further investigation. Prospective randomized studies are essential to elucidate the most effective treatment approach for this challenging patient population. This review aims to explore the potential of platinum-based chemotherapy in the context of prostate cancer, and more in detail in homologous recombination repair (HRR) mutated patients. We discuss the synergistic effects of combining platinum compounds with PARP inhibitors and the potential benefits of adopting specific therapeutic sequences.© 2023. The Author(s).